GANX (Gain Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


GANX Gain Therapeutics Inc GANX
31 GF Score
Price $1.72
! 2 Warning Signs
View Full Analysis

What is Gain Therapeutics FCF Margin %?

Gain Therapeutics GANX -1.15% 31 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates GANX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Gain Therapeutics ranks worse than 104166.56% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Gain Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-4.73 Mil. Gain Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Gain Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Gain Therapeutics's current FCF Yield % is -26.40%.

The historical rank and industry rank for Gain Therapeutics's FCF Margin % or its related term are showing as below:


During the past 8 years, the highest FCF Margin % of Gain Therapeutics was -3585.71%. The lowest was -34329.09%. And the median was -9065.41%.

GANX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

Gain Therapeutics FCF Margin % Related Terms

Gain Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Gain Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics FCF Margin % Chart

Gain Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -7,551.52 -10,579.29 -34,329.09 0.00 0.00

Gain Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GANX vs EXOZ, HYFT, MAIA: FCF Margin % Comparison

For the Biotechnology subindustry, Gain Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gain Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gain Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Gain Therapeutics's FCF Margin % falls into.


GANX
31GF Score
Gain Therapeutics Inc GANX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gain Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Gain Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-18.465/0
= %

Gain Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.728/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Gain Therapeutics (GANX) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gain Therapeutics and its competitors. According to the industry distribution chart, Gain Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is Gain Therapeutics' FCF Margin % too high?
Gain Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Gain Therapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gain Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' FCF Margin % compare to EXOZ and HYFT?
According to the Biotechnology industry distribution chart, Gain Therapeutics ranks #999999 out of 960 companies for FCF Margin %. This places Gain Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gain Therapeutics and its competitors. Gain Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Gain Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gain Therapeutics Business Description

Address 4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
31GF Score

Get the complete analysis for GANX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price